Exposure of rat hippocampal neurons to amyloid β peptide (25–35) induces the inactivation of phosphatidyl inositol-3 kinase and the activation of tau protein kinase I/glycogen synthase kinase-3β

Alzheimer's disease: the amyloid cascade hypothesis

Hardy, J. A., & Higgins, G. A. (1992) · Science · doi:10.1126/science.1566067 · Cited by 7,484

Neurotrophic and Neurotoxic Effects of Amyloid β Protein: Reversal by Tachykinin Neuropeptides

Yankner, B. A., Duffy, L. K., & Kirschner, D. A. (1990) · Science · doi:10.1126/science.2218531 · Cited by 1,975

beta-Amyloid peptides destabilize calcium homeostasis and render human cortical neurons vulnerable to excitotoxicity

Mattson, M. P., Cheng, B., Davis, D. G., Bryant, K., Lieberburg, I. M., & Rydel, R. E. (1992) · Journal of Neuroscience · doi:10.1523/jneurosci.12-02-00376.1992 · Cited by 1,633

Neurodegeneration induced by beta-amyloid peptides in vitro: the role of peptide assembly state

Pike, C., Burdick, D., Walencewicz, A., Glabe, C., & Cotman, C. (1993) · The Journal of Neuroscience · doi:10.1523/jneurosci.13-04-01676.1993 · Cited by 1,417

Requirement for Phosphatidylinositol-3 Kinase in the Prevention of Apoptosis by Nerve Growth Factor

Yao, R., & Cooper, G. M. (1995) · Science · doi:10.1126/science.7701324 · Cited by 1,393

Wortmannin is a potent phosphatidylinositol 3-kinase inhibitor: the role of phosphatidylinositol 3,4,5-trisphosphate in neutrophil responses

Arcaro, A., & Wymann, M. P. (1993) · Biochemical Journal · doi:10.1042/bj2960297 · Cited by 1,138

Structure‐Activity Analyses of β‐Amyloid Peptides: Contributions of the β25–35 Region to Aggregation and Neurotoxicity

Pike, C. J., Walencewicz‐Wasserman, A. J., Kosmoski, J., Cribbs, D. H., Glabe, C. G., & Cotman, C. W. (1995) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.1995.64010253.x · Cited by 699

β-Amyloid fibrils induce tau phosphorylation and loss of microtubule binding

Busciglio, J., Lorenzo, A., Yeh, J., & Yankner, B. A. (1995) · Neuron · doi:10.1016/0896-6273(95)90232-5 · Cited by 595

Glycogen synthase kinase-3 is rapidly inactivated in response to insulin and phosphorylates eukaryotic initiation factor eIF-2B

Welsh, G. I., & Proud, C. G. (1993) · Biochemical Journal · doi:10.1042/bj2940625 · Cited by 397

Tau protein kinase I is essential for amyloid beta-protein-induced neurotoxicity.

Takashima, A., Noguchi, K., Sato, K., Hoshino, T., & Imahori, K. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.16.7789 · Cited by 385

Cellular survival: a play in three Akts

Datta, S. R., Brunet, A., & Greenberg, M. E. (1999) · Genes & Development · doi:10.1101/gad.13.22.2905 · Cited by 4,216

The multifaceted roles of glycogen synthase kinase 3β in cellular signaling

Grimes, C. A., & Jope, R. S. (2001) · Progress in Neurobiology · doi:10.1016/s0301-0082(01)00011-9 · Cited by 1,440

The GSK3 hypothesis of Alzheimer’s disease

Hooper, C., Killick, R., & Lovestone, S. (2008) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2007.05194.x · Cited by 1,191

Decreased nuclear β‐catenin, tau hyperphosphorylation and neurodegeneration in GSK‐3β conditional transgenic mice

Lucas, J. J., Hernández, F., Gómez‐Ramos, P., Morán, M. A., Hen, R., & Avila, J. (2001) · The EMBO Journal · doi:10.1093/emboj/20.1.27 · Cited by 913

Glycogen synthase kinase-3 (GSK3): Inflammation, diseases, and therapeutics

Jope, R. S., Yuskaitis, C. J., & Beurel, E. (2007) · Neurochemical Research · doi:10.1007/s11064-006-9128-5 · Cited by 774

Docosahexaenoic acid protects from dendritic pathology in an Alzheimer's disease mouse model

Calon, F., Lim, G. P., Yang, F., Morihara, T., Teter, B., Ubeda, O., Rostaing, P., Triller, A., Salem, N., Ashe, K. H., et al. (2004) · Neuron · doi:10.1016/j.neuron.2004.08.013 · Cited by 707

Tau protein kinases: Involvement in Alzheimer's disease

Martin, L., Latypova, X., Wilson, C. M., Magnaudeix, A., Perrin, M.-L., Yardin, C., & Terro, F. (2013) · Ageing Research Reviews · doi:10.1016/j.arr.2012.06.003 · Cited by 631

Tau phosphorylation in neuronal cell function and dysfunction

Johnson, G. V. W., & Stoothoff, W. H. (2004) · Journal of Cell Science · doi:10.1242/jcs.01558 · Cited by 624

Structural Insights and Biological Effects of Glycogen Synthase Kinase 3-specific Inhibitor AR-A014418

Bhat, R. V., Xue, Y., von Berg, S., Hellberg, S., Ormö, M., Nilsson, Y., Radesäter, A., Jerning, E., Markgren, P.-O., Borgegård, T., et al. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m306268200 · Cited by 568

-Amyloid Oligomers Induce Phosphorylation of Tau and Inactivation of Insulin Receptor Substrate via c-Jun N-Terminal Kinase Signaling: Suppression by Omega-3 Fatty Acids and Curcumin

Ma, Q.-L., Yang, F., Rosario, E. R., Ubeda, O. J., Beech, W., Gant, D. J., Chen, P. P., Hudspeth, B., Chen, C., Zhao, Y., et al. (2009) · Journal of Neuroscience · doi:10.1523/jneurosci.1071-09.2009 · Cited by 536

Untangling tau hyperphosphorylation in drug design for neurodegenerative diseases

Mazanetz, M. P., & Fischer, P. M. (2007) · Nature Reviews Drug Discovery · doi:10.1038/nrd2111 · Cited by 459

GSK-3β, a pivotal kinase in Alzheimer disease

Llorens-Marítin, M., Jurado, J., Hernández, F., & Ávila, J. (2014) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2014.00046 · Cited by 451

Recent advances in the multitarget‐directed ligands approach for the treatment of Alzheimer's disease

Leon, R. M., García, A. G., & Marco, J. L. (2011) · Medicinal Research Reviews · doi:10.1002/med.20248 · Cited by 447

Presenilin 1 associates with glycogen synthase kinase-3β and its substrate tau

Takashima, A., Murayama, M., Murayama, O., Kohno, T., Honda, T., Yasutake, K., Nihonmatsu, N., Mercken, M. H., Yamaguchi, H., Sugihara, S., et al. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.16.9637 · Cited by 409

Glycogen synthase kinase 3: a drug target for CNS therapies

Bhat, R. V., Haeberlein, S. L. B., & Ávila, J. (2004) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2004.02422.x · Cited by 415

GSK-3 is essential in the pathogenesis of Alzheimer's disease

Takashima, A. (2006) · Journal of Alzheimer s Disease · doi:10.3233/jad-2006-9s335 · Cited by 403

α-synuclein in the pathophysiology of Alzheimer’s disease

Twohig, D., & Nielsen, H. M. (2019) · Molecular Neurodegeneration · doi:10.1186/s13024-019-0320-x · Cited by 374

GSK3 and tau: Two convergence points in Alzheimer’s disease

Hernandez, F., Lucas, J. J., & Avila, J. (2012) · Journal of Alzheimer's Disease · doi:10.3233/jad-2012-129025 · Cited by 359

Tau-targeting therapies for Alzheimer disease: Current status and future directions

Congdon, E. E., Ji, C., Tetlow, A. M., Jiang, Y., & Sigurdsson, E. M. (2023) · Nature Reviews Neurology · doi:10.1038/s41582-023-00883-2 · Cited by 371

MicroRNA-125b induces tau hyperphosphorylation and cognitive deficits in Alzheimer’s disease

Banzhaf‐Strathmann, J., Benito, E., May, S., Arzberger, T., Tahirovic, S., Kretzschmar, H., Fischer, A., & Edbauer, D. (2014) · The EMBO Journal · doi:10.15252/embj.201387576 · Cited by 347

Insulin-degrading Enzyme as a Downstream Target of Insulin Receptor Signaling cascade: Implications for Alzheimer's Disease Intervention

Zhao, L., Teter, B., Morihara, T., Lim, G. P., Ambegaokar, S. S., Ubeda, O. J., Frautschy, S. A., & Cole, G. M. (2004) · The Journal of Neuroscience · doi:10.1523/jneurosci.2860-04.2004 · Cited by 329

Wnt signaling in the nervous system and in Alzheimer's disease

Inestrosa, N. C., & Varela-Nallar, L. (2014) · Journal of Molecular Cell Biology · doi:10.1093/jmcb/mjt051 · Cited by 324

Spatial learning deficit in transgenic mice that conditionally over‐express GSK‐3β in the brain but do not form tau filaments

Hernández, F., Borrell, J., Guaza, C., Avila, J., & Lucas, J. J. (2002) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2002.01269.x · Cited by 372

GSK-3 and tau: a key duet in Alzheimer’s disease

Sayas, C. L., & Ávila, J. (2021) · Cells · doi:10.3390/cells10040721 · Cited by 314

Amyloid Activates GSK-3β to Aggravate Neuronal Tauopathy in Bigenic Mice

Terwel, D., Muyllaert, D., Dewachter, I., Borghgraef, P., Croes, S., Devijver, H., & Van Leuven, F. (2008) · The American Journal of Pathology · doi:10.2353/ajpath.2008.070904 · Cited by 300

Wnt signaling function in Alzheimer’s disease

Ferrari, G. V. D., & Inestrosa, N. C. (2000) · Brain Research Reviews · doi:10.1016/s0165-0173(00)00021-7 · Cited by 289

Activation of tau protein kinase I/glycogen synthase kinase-3β by amyloid β peptide (25–35) enhances phosphorylation of tau in hippocampal neurons

Takashima, A., Honda, T., Yasutake, K., Michel, G., Murayama, O., Murayama, M., Ishiguro, K., & Yamaguchi, H. (1998) · Neuroscience Research · doi:10.1016/s0168-0102(98)00061-3 · Cited by 287

Full Reversal of Alzheimer's Disease-Like Phenotype in a Mouse Model with Conditional Overexpression of Glycogen Synthase Kinase-3

Engel, T., Hernández, F., Ávila, J., & Lucas, J. J. (2006) · Journal of Neuroscience · doi:10.1523/jneurosci.0604-06.2006 · Cited by 262

Nuclear factor erythroid 2-related factor 2 protects against beta amyloid

Kanninen, K. M., Malm, T., Jyrkkänen, H.-K., Goldsteins, G., Keksa-Goldsteine, V., Tanila, H., Yamamoto, M. P., Ylä‐Herttuala, S., Levonen, A., & Koıstınaho, J. (2008) · Molecular and Cellular Neuroscience · doi:10.1016/j.mcn.2008.07.010 · Cited by 259

Developmental expression and localization of glycogen synthase kinase-3β in rat brain

Leroy, K., & Brion, J. (1999) · Journal of Chemical Neuroanatomy · doi:10.1016/s0891-0618(99)00012-5 · Cited by 242

GSK‐3β down‐regulates the transcription factor Nrf2 after oxidant damage: relevance to exposure of neuronal cells to oxidative stress

Rojo, A. I., de Sagarra, M. R., & Cuadrado, A. (2007) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2007.05124.x · Cited by 246

Modulation of proteostasis by transcription factor NRF2 and impact in neurodegenerative diseases

Pajares, M., Cuadrado, A., & Rojo, A. I. (2017) · Redox Biology · doi:10.1016/j.redox.2017.01.006 · Cited by 226

Neuroprotective effects of salidroside against beta-amyloid-induced oxidative stress in SH-SY5Y human neuroblastoma cells.

Zhang, L., Yu, H.-M., Zhao, X., Lin, X.-F., Tan, C., Cao, G.-X., & Wang, Z.-W. (2010) · Neurochemistry International · doi:10.1016/j.neuint.2010.06.021 · Cited by 215

Mercury Induces Cell Cytotoxicity and Oxidative Stress and Increases β‐Amyloid Secretion and Tau Phosphorylation in SHSY5Y Neuroblastoma Cells

Olivieri, G., Brack, C., Müller-Spahn, F., Stähelin, H. B., i, M. H., Renard, P., Brockhaus, M., & Hock, C. (2000) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2000.0740231.x · Cited by 212

Lithium and bipolar mood disorder: the inositol-depletion hypothesis revisited

Harwood, A. J. (2004) · Molecular Psychiatry · doi:10.1038/sj.mp.4001618 · Cited by 209

β-Amyloid impairs axonal BDNF retrograde trafficking

Poon, W. W., Blurton-Jones, M. M., Tu, C. H., Feinberg, L. M., Chabrier, M. A., Harris, J. W., Jeon, N. L., & Cotman, C. W. (2009) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2009.05.012 · Cited by 203

The GSK3β signaling cascade and neurodegenerative disease

Kaytor, M. D. (2002) · Current Opinion in Neurobiology · doi:10.1016/s0959-4388(02)00320-3 · Cited by 198

Chronic lithium administration to FTDP‐17 tau and GSK‐3β overexpressing mice prevents tau hyperphosphorylation and neurofibrillary tangle formation, but pre‐formed neurofibrillary tangles do not revert

Engel, T., Goñi‐Oliver, P., Lucas, J. J., Avila, J., & Hernández, F. (2006) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2006.04139.x · Cited by 223

The active form of glycogen synthase kinase-3? is associated with granulovacuolar degeneration in neurons in Alzheimer's disease

Boutajangout, A., Leroy, K., Authelet, M., Anderton, B. H., Brion, J., & Woodgett, J. R. (2002) · Acta Neuropathologica · doi:10.1007/s004010100435 · Cited by 190

Akt: Versatile Mediator of Cell Survival and Beyond

Kim, D., & Chung, J. (2002) · BMB Reports · doi:10.5483/bmbrep.2002.35.1.106 · Cited by 184

GSK‐3 in Neurodegenerative Diseases

Lei, P., Ayton, S., Bush, A. I., & Adlard, P. A. (2011) · International Journal of Alzheimer’s Disease · doi:10.4061/2011/189246 · Cited by 177

Glycogen synthase kinase-3 inhibitors: Rescuers of cognitive impairments

King, M. K., Pardo, M., Cheng, Y., Downey, K., Jope, R. S., & Beurel, E. (2013) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2013.07.010 · Cited by 177

Voluntary Running Attenuates Memory Loss, Decreases Neuropathological Changes and Induces Neurogenesis in a Mouse Model of A lzheimer's Disease

Tapia‐Rojas, C., Aránguiz, F. C., Varela‐Nallar, L., & Inestrosa, N. C. (2015) · Brain Pathology · doi:10.1111/bpa.12255 · Cited by 176

Glycogen synthase kinase 3β and Alzheimer’s disease: pathophysiological and therapeutic significance

Balaraman, Y., Limaye, A. R., Levey, A. I., & Srinivasan, S. (2006) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-005-5597-y · Cited by 172

Tau reduction prevents Aβ-induced axonal transport deficits by blocking activation of GSK3β

Vossel, K. A., Xu, J. C., Fomenko, V., Miyamoto, T., Suberbielle, E., Knox, J. A., Ho, K., Kim, D. H., Yu, G.-Q., & Mucke, L. (2015) · Journal of Cell Biology · doi:10.1083/jcb.201407065 · Cited by 167

Tau and Tauopathies

Lee, G. S., & Leugers, C. J. (2012) · Progress in molecular biology and translational science · doi:10.1016/b978-0-12-385883-2.00004-7 · Cited by 173

GSK3 Function in the Brain during Development, Neuronal Plasticity, and Neurodegeneration

Salcedo‐Tello, P., Ortiz‐Matamoros, A., & Arias, C. (2011) · International Journal of Alzheimer s Disease · doi:10.4061/2011/189728 · Cited by 173

Wnts in adult brain: from synaptic plasticity to cognitive deficiencies

Oliva, C. A., Vargas, J. Y., & Inestrosa, N. C. (2013) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2013.00224 · Cited by 162

HIV‐1 Tat‐Mediated Activation of Glycogen Synthase Kinase‐3β Contributes to Tat‐Mediated Neurotoxicity

Maggirwar, S. B., Tong, N., Ramirez, S. H., Gelbard, H. A., & Dewhurst, S. (1999) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.1999.0730578.x · Cited by 168

Blockade of Tau Hyperphosphorylation and Aβ1–42 Generation by the Aminotetrahydrofuran Derivative ANAVEX2-73, a Mixed Muscarinic and σ1 Receptor Agonist, in a Nontransgenic Mouse Model of Alzheimer’s Disease

Lahmy, V., Meunier, J., Malmström, S., Naert, G., Givalois, L., Kim, S. H., Villard, V., Vamvakides, A., & Maurice, T. (2013) · Neuropsychopharmacology · doi:10.1038/npp.2013.70 · Cited by 165

Deconstructing GSK‐3: The Fine Regulation of Its Activity

Medina, M., & Wandosell, F. G. (2011) · International Journal of Alzheimer s Disease · doi:10.4061/2011/479249 · Cited by 170

GSK-3β at the Intersection of Neuronal Plasticity and Neurodegeneration

Jaworski, T., Banach, E., & Gralec, K. (2019) · Neural Plasticity · doi:10.1155/2019/4209475 · Cited by 167

GSK3β and tau protein in Alzheimer's disease and epilepsy

Toral-Rios, D., Pichardo-Rojas, P. S., Alonso-Vanegas, M., & Campos-Peña, V. (2020) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2020.00019 · Cited by 158

Glycogen Synthase Kinase 3 Inhibition Promotes Lysosomal Biogenesis and Autophagic Degradation of the Amyloid-β Precursor Protein

Parr, C., Carzaniga, R., Gentleman, S., LEUVEN, F. V., Walter, J., & Sastre, M. (2012) · Molecular and Cellular Biology · doi:10.1128/mcb.00930-12 · Cited by 155

Pyrrolidine Dithiocarbamate Activates Akt and Improves Spatial Learning in APP/PS1 Mice without Affecting β-Amyloid Burden

Malm, T., Iivonen, H., Goldsteins, G., Keksa-Goldsteine, V., Ahtoniemi, T., Kanninen, K. M., Salminen, A., Auriola, S. O. K., van Groen, T., Tanila, H., et al. (2007) · Journal of Neuroscience · doi:10.1523/jneurosci.0059-07.2007 · Cited by 157

Flavonoid‐mediated presenilin‐1 phosphorylation reduces Alzheimer's disease β‐amyloid production

Rezai-Zadeh, K. P., Shytle, R. D., Bai, Y., Tian, J., Hou, H., Mori, T., Zeng, J., Obregon, D. F., Town, T., & Tan, J. (2008) · Journal of Cellular and Molecular Medicine · doi:10.1111/j.1582-4934.2008.00344.x · Cited by 155

GSK‐3: A key player in neurodegeneration and memory

Giese, K.-P. (2009) · IUBMB Life · doi:10.1002/iub.187 · Cited by 152

Neuronal apolipoprotein E4 increases cell death and phosphorylated tau release in alzheimer disease

Wadhwani, A. R., Affaneh, A., Van Gulden, S., & Kessler, J. A. (2019) · Annals of Neurology · doi:10.1002/ana.25455 · Cited by 142

ER stress is involved in Aβ‐induced GSK‐3β activation and tau phosphorylation

Resende, R., Ferreiro, E. B., Pereira, C., & Oliveira, C. R. (2008) · Journal of Neuroscience Research · doi:10.1002/jnr.21648 · Cited by 142

Lithium and Therapeutic Targeting of GSK-3

Snitow, M. E., Bhansali, R. S., & Klein, P. S. (2021) · Cells · doi:10.3390/cells10020255 · Cited by 152

GSK-3β Is Required for Memory Reconsolidation in Adult Brain

Kimura, T., Yamashita, S., Nakao, S., Park, J.-M., Murayama, M., Mizoroki, T., Yoshiike, Y., Sahara, N., & Takashima, A. (2008) · PLoS ONE · doi:10.1371/journal.pone.0003540 · Cited by 138

Normal and Pathological Tau Proteins as Factors for Microtubule Assembly

Delacourte, A., & Buée, L. (1997) · International review of cytology · doi:10.1016/s0074-7696(08)62588-7 · Cited by 145

New Insights Into Drug Discovery Targeting Tau Protein

Soeda, Y., & Takashima, A. (2020) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2020.590896 · Cited by 136

Tau phosphorylation and tau mislocalization mediate soluble Aβ oligomer‐induced AMPA glutamate receptor signaling deficits

Miller, E. C., Teravskis, P. J., Dummer, B. W., Zhao, X., Huganir, R. L., & Liao, D. (2014) · European Journal of Neuroscience · doi:10.1111/ejn.12507 · Cited by 131

Search for a common mechanism of mood stabilizers

Harwood, A. J., & Agam, G. (2003) · Biochemical Pharmacology · doi:10.1016/s0006-2952(03)00187-4 · Cited by 134

Therapeutic strategies for tau mediated neurodegeneration

Yoshiyama, Y., Lee, V. M. ‐., & Trojanowski, J. Q. (2012) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp-2012-303144 · Cited by 137

The pleiotropic effects of omega-3 docosahexaenoic acid on the hallmarks of Alzheimer's disease

Belkouch, M., Hachem, M., Elgot, A., Van, A. L., Picq, M., Guichardant, M., Lagarde, M., & Bernoud‐Hubac, N. (2016) · The Journal of Nutritional Biochemistry · doi:10.1016/j.jnutbio.2016.03.002 · Cited by 131

Signal transduction during amyloid-β-peptide neurotoxicity: role in Alzheimer disease

Fuentealba, R. A., Farı́as, G. G., Scheu, J., Bronfman, M., Marzolo, M., & Inestrosa, N. C. (2004) · Brain Research Reviews · doi:10.1016/j.brainresrev.2004.07.018 · Cited by 126

Amyloid-beta-induced neurotoxicity is reduced by inhibition of glycogen synthase kinase-3

Koh, S., Noh, M., & Kim, S. H. (2007) · Brain Research · doi:10.1016/j.brainres.2007.10.064 · Cited by 126

Impaired Wnt Signaling in the Prefrontal Cortex of Alzheimer’s Disease

Folke, J., Pakkenberg, B., & Brudek, T. (2019) · Molecular Neurobiology · doi:10.1007/s12035-018-1103-z · Cited by 123

Epigenetically regulated microRNAs in Alzheimer's disease

van den Hove, D., Kompotis, K., Lardenoije, R., Kenis, G., Mill, J. S., Steinbusch, H. W. M., Lesch, K., Fitzsimons, C. P., Strooper, B. D., & Rutten, B. P. F. (2013) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2013.10.082 · Cited by 121

Mitochondrial dysfunction and tau hyperphosphorylation in Ts1Cje, a mouse model for Down syndrome

Ebrahim, A. S., Shimohata, A., Akagi, T., Yu, W., Yamaguchi, M., Murayama, M., Chui, D., Takeuchi, T., Amano, K., Subramhanya, K. H., et al. (2006) · Human Molecular Genetics · doi:10.1093/hmg/ddl211 · Cited by 119

Hyperphosphorylation of Tau Induced by Naturally Secreted Amyloid-β at Nanomolar Concentrations Is Modulated by Insulin-dependent Akt-GSK3β Signaling Pathway

Tokutake, T., Kasuga, K., Yajima, R., Sekine, Y., Tezuka, T., Nishizawa, M., & Ikeuchi, T. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.m112.348300 · Cited by 124

Structural and Functional Implications of Tau Hyperphosphorylation: Information from Phosphorylation-Mimicking Mutated Tau Proteins

Eidenmüller, J., Fath, T., Hellwig, A., Reed, J., Sontag, E., & Brandt, R. (2000) · Biochemistry · doi:10.1021/bi001290z · Cited by 117

Regulation of tau phosphorylation and protection against β‐amyloid‐induced neurodegeneration by lithium. Possible implications for Alzheimer's disease

Alvarez, G., Muñoz-Montaño, J. R., Satrústegui, J., Ávila, J., Bogónez, E., & Díaz‐Nido, J. (2002) · Bipolar Disorders · doi:10.1034/j.1399-5618.2002.01150.x · Cited by 116

Iron-induced oxidative stress modify tau phosphorylation patterns in hippocampal cell cultures

Egaña, J. T., Zambrano, C. A., Núñez, M. T., González-Billault, C. E., & Maccioni, R. B. (2003) · BioMetals · doi:10.1023/a:1020727218493 · Cited by 114

Tissue plasminogen activator mediates amyloid‐induced neurotoxicity via Erk1/2 activation

Medina, M. G., Ledesma, M. D., Domínguez, J. E., Medina, M., Zafra, D., Alameda, F., Dotti, C. G., & Navarro, P. (2005) · The EMBO Journal · doi:10.1038/sj.emboj.7600650 · Cited by 114

Cooexpression of FTDP-17 tau and GSK-3β in transgenic mice induce tau polymerization and neurodegeneration

Engel, T., Lucas, J. J., Gómez‐Ramos, P., Morán, M. A., Ávila, J., & Hernández, F. (2005) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2005.06.010 · Cited by 111

Truncation and activation of GSK-3β by calpain I: a molecular mechanism links to tau hyperphosphorylation in Alzheimer's disease

Jin, N., Yin, X., Yu, D., Cao, M., Gong, C., Iqbal, K., Ding, F., Gu, X., & Liu, F. (2015) · Scientific Reports · doi:10.1038/srep08187 · Cited by 111

Icariin attenuates β-amyloid-induced neurotoxicity by inhibition of tau protein hyperphosphorylation in PC12 cells

Zeng, K., Ko, H., Yang, H. O., & Wang, X. (2010) · Neuropharmacology · doi:10.1016/j.neuropharm.2010.07.020 · Cited by 106

Untangling Tau and Iron: Exploring the Interaction Between Iron and Tau in Neurodegeneration

Rao, S. S., & Adlard, P. A. (2018) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2018.00276 · Cited by 108

O‐linked N‐acetylglucosamine levels in cerebellar neurons respond reciprocally to pertubations of phosphorylation

Griffith, L. S., & Schmitz, B. (1999) · European Journal of Biochemistry · doi:10.1046/j.1432-1327.1999.00439.x · Cited by 104

Tau phosphorylation increases in symptomatic mice overexpressing A30P α-synuclein

Frasier, M. A., Walzer, M., McCarthy, L., Magnuson, D. J., Lee, J. M., Haas, C. A., Kahle, P. J., & Wolozin, B. L. (2004) · Experimental Neurology · doi:10.1016/j.expneurol.2004.07.016 · Cited by 103

The novel histone de acetylase 6 inhibitor, MPT0G211, ameliorates tau phosphorylation and cognitive deficits in an Alzheimer’s disease model

Fan, S.-J., Huang, F.-I., Liou, J., & Yang, C. (2018) · Cell Death and Disease · doi:10.1038/s41419-018-0688-5 · Cited by 105

The interactions of p53 with tau and Aß as potential therapeutic targets for Alzheimer’s disease

Jembrek, M. J., Slade, N., Hof, P. R., & Šimić, G. (2018) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2018.05.001 · Cited by 101

N‐Acetyl‐ l ‐cysteine protects SHSY5Y neuroblastoma cells from oxidative stress and cell cytotoxicity: effects on β‐amyloid secretion and tau phosphorylation

Olivieri, G., Baysang, G., Meier, F., Müller-Spahn, F., Stähelin, H. B., Brockhaus, M., & Brack, C. (2001) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2001.00090.x · Cited by 98

The selective GSK3 inhibitor, SAR502250, displays neuroprotective activity and attenuates behavioral impairments in models of neuropsychiatric symptoms of Alzheimer's disease in rodents

Griebel, G., Stemmelin, J., Lopez-Grancha, M., Boulay, D., Boquet, G., Slowinski, F., Pichat, P., Beeské, S., Tanaka, S., Mori, A., et al. (2019) · Scientific Reports · doi:10.1038/s41598-019-54557-5 · Cited by 97

Apolipoprotein E and β‐amyloid (1–42) regulation of glycogen synthase kinase‐3β

Cedazo-Mı́nguez, Á., Popescu, B. O., Blanco‐Millán, J. M., Akterin, S., Pei, J. ‐., Winblad, B. G., & Cowburn, R. F. (2003) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2003.02088.x · Cited by 99

Age-related changes in glycogen synthase kinase 3β (GSK3β) immunoreactivity in the central nervous system of rats

Lee, S. J., Chung, Y. H., Joo, K. M., Lim, H. C., Jeon, G. S., Kim, D., Lee, W. B., Kim, Y. S., & Ik, C. (2006) · Neuroscience Letters · doi:10.1016/j.neulet.2006.09.026 · Cited by 96

Glycogen synthase kinase 3β inhibitor Chir025 reduces neuronal death resulting from oxygen-glucose deprivation, glutamate excitotoxicity, and cerebral ischemia

Kelly, S., Zhao, H., Sun, G. H., Cheng, D., Qiao, Y., Luo, J., Martin, K., Steinberg, G. K., Harrison, S. D., & Yenari, M. A. (2004) · Experimental Neurology · doi:10.1016/j.expneurol.2004.04.004 · Cited by 95

Inhibition of glycogen synthase kinase 3β is involved in the resistance to oxidative stress in neuronal HT22 cells

Schäfer, M., Goodenough, S., Moosmann, B., & Behl, C. (2004) · Brain Research · doi:10.1016/j.brainres.2004.01.037 · Cited by 93

Wnt signaling: Role in LTP, neural networks and memory

Oliva, C. A., Vargas, J., & Inestrosa, N. C. (2013) · Ageing Research Reviews · doi:10.1016/j.arr.2013.03.006 · Cited by 92

Recent developments of protein kinase inhibitors as potential AD therapeutics

Tell, V., & Hilgeroth, A. (2013) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2013.00189 · Cited by 92

Three-Dimensional Structures of the Amyloid β Peptide (25−35) in Membrane-Mimicking Environment

Kohno, T., Kobayashi, K., Maeda, T., Sato, K., & Takashima, A. (1996) · Biochemistry · doi:10.1021/bi961598j · Cited by 90

Akt/GSK3β serine/threonine kinases: evidence for a signalling pathway mediated by familial Alzheimer's disease mutations

Ryder, J. W., Yuan, S., & Ni, B. (2003) · Cellular Signalling · doi:10.1016/j.cellsig.2003.07.004 · Cited by 92

Frizzled‐1 is involved in the neuroprotective effect of Wnt3a against Aβ oligomers

Chacón, M. A., Varela‐Nallar, L., & Inestrosa, N. C. (2008) · Journal of Cellular Physiology · doi:10.1002/jcp.21497 · Cited by 87

Oxidative stress promotes $tau; dephosphorylation in neuronal cells: the roles of cdk5 and PP1

Zambrano, C. A., Egaña, J. T., Núñez, M. T., Maccioni, R. B., & González-Billault, C. E. (2004) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2004.03.007 · Cited by 90

Role of GSK‐3β in Alzheimer's disease pathology

Planel, E., Sun, X., & Takashima, A. (2002) · Drug Development Research · doi:10.1002/ddr.10100 · Cited by 87

Regulation of Cell Survival Mechanisms in Alzheimer′s Disease by Glycogen Synthase Kinase‐3

Mines, M. A., Beurel, E., & Jope, R. S. (2011) · International Journal of Alzheimer s Disease · doi:10.4061/2011/861072 · Cited by 88

GSK3β Signalling: Casting a Wide Net in Alzheimer’s Disease

Bhat, R. V., & Budd, S. L. (2002) · Neurosignals · doi:10.1159/000067423 · Cited by 85

Activation of tau protein kinase I/glycogen synthase kinase-3β by amyloid β peptide (25–35) enhances phosphorylation of tau in hippocampal neurons

Takashima, A., Honda, T., Yasutake, K., Michel, G., Murayama, O., Murayama, M., Ishiguro, K., & Yamaguchi, H. (1998) · Neuroscience Research · doi:10.1016/s0168-0102(98)00061-3 · Cited by 287

Amyloid β peptide induces cytoplasmic accumulation of amyloid protein precursor via tau protein kinase I/glycogen synthase kinase-3β in rat hippocampal neurons

Takashima, A., Yamaguchi, H., Noguchi, K., Michel, G., Ishiguro, K., Sato, K., Hoshino, T., Hoshi, M. M., & Imahori, K. (1995) · Neuroscience Letters · doi:10.1016/0304-3940(95)11964-x · Cited by 54

Physiologic Levels of β‐Amyloid Activate Phosphatidylinositol 3‐Kinase with the Involvement of Tyrosine Phosphorylation

Luo, Y., Sunderland, T., & Wolozin, B. L. (1996) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.1996.67030978.x · Cited by 39

[Involvement of tau protein kinase in amyloid-beta-induced neurodegeneration].

Ishiguro, K. (1998) · PubMed · Cited by 6

β-Amyloid peptide toxicity in organotypic hippocampal slice culture involves Akt/PKB, GSK-3β, and PTEN

Nassif, M., Hoppe, J. B., Santin, K., Frozza, R. L., Zamin, L. L., Simão, F., Horn, A. P., & Salbego, C. G. (2006) · Neurochemistry International · doi:10.1016/j.neuint.2006.08.008 · Cited by 52